Telmisartan 80mg Non-responder Trial

Exclusion Criteria

• •Patients taking 3 or more antihypertensive drugs at signing the informed consent form
• •Patients with known or suspected secondary hypertension
• •Patients with clinically relevant cardiac arrhythmia
• •Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
• •Patients with recent cardiovascular events
• •Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form
• •Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
• •Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
• •Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs
• •Patients with hepatic and/or renal dysfunction
• •Pre-menopausal women who are nursing or pregnant